Results 121 to 130 of about 43,704 (225)

Synergistic Anti‐Lung Cancer Effects of Cytarabine and a NCBI‐Registered Streptococcus via Modulation of Apoptotic and Survival Pathways

Food Science &Nutrition, Volume 14, Issue 8, August 2026.
Schematic overview of the synergistic anticancer mechanism between Streptococcus thermophilus Ab.342 SH and Cytarabine (CYT) (Ara‐C) in A549 human lung adenocarcinoma cells. The probiotic strain, isolated from traditional dairy samples collected in Fars Province, was cultured to obtain its cell‐free supernatant (CFS) containing bioactive metabolites ...
Abbas Asoudeh‐Fard, Farnood Afrakhteh, Zahra Rahimi, Rakhshan Hakimelahi, Mohammad Bagher Nazari, Mohamad Mehdi Nemati, Abbas Fazlinia, Asghar Parsaei   +7 more
wiley   +1 more source

Intensive Induction in AML in the Era of Venetoclax: A Standing Count for “7 + 3”?

American Journal of Hematology, Volume 101, Issue 8, Page 1783-1789, August 2026.
Sudhir Tauro, Ayalew Tefferi
wiley   +1 more source

Venetoclax plus azacitidine, low‐dose cytarabine, aclarubicin, and G‐CSF (VA‐CAG regimen) for newly diagnosed young patients with acute myeloid leukemia: A prospective, multicenter, single‐arm Phase II clinical trial

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract We conducted a prospective, multicenter, Phase II study to evaluate the safety and efficacy of venetoclax/azacitidine/low‐dose cytarabine/aclarubicin/granulocyte colony‐stimulating factor (G‐CSF) (VA‐CAG) in young patients with newly diagnosed acute myeloid leukemia (ND‐AML). The VA‐CAG regimen included venetoclax (100 mg/day, Days 1–2; 200 mg,
Xiaoping Li, Qiurong Zhang, Xiaoyan Li, Lin Liu, Yonglin Shen, Yu Li, Lihui Peng, Chaoyang Zhou, Chie Qiu, Zhongtao Yuan, Shiqian Hou, Youcheng Wang, Lihua Zhang, Jingqiong Li, Liang Zhao, Qiuyuan Tang, Zucong Chen, Jing Feng, Xuejuan Zhang, Guoxiu Bao, Kui Zhang, Renpeng Zhang, Shiqi Li, Yingnian Chen, Jianhua Rao, Yancheng Dong, Dingsong Zhang, Yueyuan Wang, Aifang Li, Xi Ye, Lei Lei, Jiao Chen, Sufen Xu, Yanling Jin, Chaoen Zheng, Yang Liang, Sanbin Wang   +36 more
wiley   +1 more source

Simultaneous Leukocytapheresis and Continuous Renal Replacement Therapy for Acute Myeloid Leukemia: A Case Report

Journal of Clinical Apheresis, Volume 41, Issue 4, August 2026.
ABSTRACT Hyperleukocytosis in acute myeloid leukemia (AML) could cause life‐threatening complications, including leukostasis and tumor lysis syndrome (TLS). While leukocytapheresis and continuous renal replacement therapy (CRRT) are typically performed independently to maintain hemodynamic stability and manage anticoagulation, their simultaneous ...
Seung Hee Cho, Dong Wook Jekarl, Yoo‐Jin Kim, Hyung Suk Cho, Su Kyung Jeon, Hye Young Kim, Inae Park, Eun Jin Kim   +7 more
wiley   +1 more source

MRI Predictors of Outcome in Primary Central Nervous System Lymphoma Patients Before and After Autologous Stem Cell Transplant

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Introduction Primary CNS lymphoma (PCNSL) is treated with intensive chemotherapy and autologous stem cell transplant (HDT‐ASCT), yet up to one‐third of patients relapse. Standard MRI response criteria may not reliably distinguish residual tumour from post‐treatment change; additional MRI sequences, such as apparent diffusion coefficient (ADC),
Dewen Meng, Hamza Alshuft, Christopher P. Fox, Stefanie Thust, Nicolas Martinez‐Calle   +4 more
wiley   +1 more source

Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource Utilization, and Costs. [PDF]

J Health Econ Outcomes Res
Dharmani C, Fofah O, Qu P, Jiang Z, Wang J, Li L, Tao Y, Song L.   +7 more
europepmc   +1 more source

Salvage With Revumenib: Targeting KMT2A‐Rearranged Isolated Leukemia Cutis Identified in the Extramedullary Disease

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT Acute myeloid leukemia (AML) is an aggressive hematologic malignancy associated with a high risk of relapse. Leukemia cutis is characterized by the presence of neoplastic leukocytes infiltrating the skin. Here, we present a previously treated AML patient who relapsed with isolated leukemia cutis without bone marrow involvement. Fluorescence in
Bana Antonios, Xuemei Wu, Lynn Johnson, Avani Ahuja, Megan Blauvelt, Margaret Aronckes, Nina Dutton, Jennifer Dujmic, Salman Fazal, Taimoor I. Sheikh   +9 more
wiley   +1 more source

Subclinical Cardiac Changes Following CPX‐351 Induction in Adults with Favorable/Intermediate‐Risk AML

eJHaem, Volume 7, Issue 4, August 2026.
ABSTRACT CPX‐351 is associated with reduced non‐hematologic toxicity, but its cardiac safety is not well defined. We prospectively assessed ejection fraction (EF) and global longitudinal strain (GLS) in younger adults with AML treated with a single CPX‐351‐based induction. Median changes were mild and comparable to standard “7 + 3”.
Chezi Ganzel, Avraham Frisch, Ofir Wolach, Yakir Moshe, Baher Krayem, Neta Dor, Jacob M Rowe, Yishai Ofran   +7 more
wiley   +1 more source

Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience. [PDF]

Ann Hematol
Kim BK, Hong KT, Choi JY, Park HJ, Kang HJ.   +4 more
europepmc   +1 more source

Nucleotide Metabolism in Health and Disease

MedComm, Volume 7, Issue 8, August 2026.
Nucleotide metabolism, including de novo synthesis, salvage pathways, and catabolism, when dysregulated contributes to cancer, immune disorders, metabolic and urological diseases, and radiation injury. Metabolites such as adenosine, cGAMP, NAD, and cAMP and enzymes like RNR are promising therapeutic targets and biomarkers.
Xiaoying Zhao, Yiyu Zeng, Yike Xu, Shu Rao, Mouna Khouchani, Hassna Soummane, Jingyi Li, Rui Liu   +7 more
wiley   +1 more source